Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a prodrug that is metabolized to SN‑38, which inhibits topoisomerase I. This inhibition prevents the re‑ligation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage and ultimately causing death of rapidly dividing cancer cells.

The dosing regimen for Irinotecan Accord is individualized. The prescribing oncologist determines the dose, schedule, and combination with other agents based on the patient’s clinical condition, body surface area, and treatment goals.

Irinotecan is classified as Pregnancy Category D, indicating evidence of fetal risk. It should not be used during pregnancy, and breastfeeding is contraindicated because the drug can be excreted in milk and may harm the infant.

To place an order, submit an enquiry on the Irinotecan Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with other colorectal‑cancer agents such as oxaliplatin or 5‑fluorouracil, Irinotecan offers a distinct mechanism by targeting topoisomerase I. It is often combined with fluoropyrimidines to enhance efficacy, but it may have a higher incidence of severe diarrhea and neutropenia, requiring careful monitoring.

Irinotecan Accord should be stored refrigerated at 2‑8 °C. Keep the solution in its original container, protect it from light, and avoid freezing or shaking. If the product must be transported, maintain the cold‑chain throughout the distribution process.

Irinotecan Accord is given as an intravenous infusion by a qualified healthcare professional. The infusion rate and duration are determined by the prescribing physician and are typically administered in a clinical setting equipped for monitoring infusion‑related reactions.

The most critical risks include severe neutropenia leading to infection, life‑threatening diarrhea, acute cholinergic syndrome, and rare hypersensitivity reactions. Patients should be monitored closely for signs of infection, gastrointestinal toxicity, and any allergic symptoms throughout treatment.

Irinotecan Accord is contraindicated in patients who are pregnant, breastfeeding, or have known hypersensitivity to irinotecan or its excipients. Caution is also advised for individuals with severe hepatic impairment, uncontrolled infections, or pre‑existing severe bone‑marrow suppression.